Do analysts prefer LNAI or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, LNAI or DCOY?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is LNAI or DCOY more profitable?

Decoy Therapeutics' return on equity of -395.42% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Decoy Therapeutics N/A -395.42% -193.30%

Do analysts prefer DCOY or GDTC?

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, DCOY or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Decoy Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A CytoMed Therapeutics $250K 46.85 -$3.10M N/A N/A

Is DCOY or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% CytoMed Therapeutics N/A N/A N/A

Is DCOY or BCDA more profitable?

Decoy Therapeutics' return on equity of -395.42% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% BioCardia N/A -5,456.14% -232.75%

Which has better valuation and earnings, CMMB or DCOY?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is CMMB or DCOY more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% Decoy Therapeutics N/A -395.42% -193.30%

Do analysts recommend DCOY or MYNZ?

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is DCOY or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% Mainz Biomed N/A N/A N/A

Decoy Therapeutics (DCOY) Competitors

$5.04 +0.10 (+2.02%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.03 -0.01 (-0.20%)

As of 07/24/2026 07:34 PM Eastern

Compare

DCOY vs. LNAI, GDTC, BCDA, CMMB, and MYNZ

Should you buy Decoy Therapeutics stock or one of its competitors? MarketBeat compares Decoy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Decoy Therapeutics include Lunai Bioworks (LNAI), CytoMed Therapeutics (GDTC), BioCardia (BCDA), Chemomab Therapeutics (CMMB), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry.

How does Decoy Therapeutics compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Decoy Therapeutics' return on equity of -395.42% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lunai Bioworks has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

In the previous week, Decoy Therapeutics had 1 more articles in the media than Lunai Bioworks. MarketBeat recorded 2 mentions for Decoy Therapeutics and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.89 beat Decoy Therapeutics' score of 1.44 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
Decoy Therapeutics	Positive

Summary

Decoy Therapeutics beats Lunai Bioworks on 9 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to CytoMed Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

CytoMed Therapeutics has higher revenue and earnings than Decoy Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
CytoMed Therapeutics	$250K	46.85	-$3.10M	N/A	N/A

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decoy Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

CytoMed Therapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
CytoMed Therapeutics	N/A	N/A	N/A

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 1.7% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Decoy Therapeutics had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for Decoy Therapeutics and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.87 beat Decoy Therapeutics' score of 1.44 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Decoy Therapeutics	Positive
CytoMed Therapeutics	Very Positive

Summary

Decoy Therapeutics beats CytoMed Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to BioCardia?

Decoy Therapeutics (NASDAQ:DCOY) and BioCardia (NASDAQ:BCDA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Decoy Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

In the previous week, Decoy Therapeutics and Decoy Therapeutics both had 2 articles in the media. Decoy Therapeutics' average media sentiment score of 1.44 beat BioCardia's score of 0.44 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Positive
BioCardia	Neutral

Decoy Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 495.24%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,840.83%. Given BioCardia's higher probable upside, analysts plainly believe BioCardia is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioCardia	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioCardia has higher revenue and earnings than Decoy Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
BioCardia	$60K	161.24	-$8.23M	-$0.91	N/A

Decoy Therapeutics' return on equity of -395.42% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
BioCardia	N/A	-5,456.14%	-232.75%

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by insiders. Comparatively, 17.4% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BioCardia beats Decoy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Decoy Therapeutics compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Decoy Therapeutics had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for Decoy Therapeutics and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat Decoy Therapeutics' score of 1.44 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
Decoy Therapeutics	Positive

Chemomab Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 1,738.24%. Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 495.24%. Given Chemomab Therapeutics' higher probable upside, research analysts clearly believe Chemomab Therapeutics is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Chemomab Therapeutics' return on equity of -89.03% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Summary

Chemomab Therapeutics beats Decoy Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Decoy Therapeutics compare to Mainz Biomed?

Decoy Therapeutics (NASDAQ:DCOY) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Decoy Therapeutics has higher earnings, but lower revenue than Mainz Biomed. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Mainz Biomed	$659.94K	14.83	-$21.65M	-$65.60	N/A

In the previous week, Decoy Therapeutics had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Decoy Therapeutics and 1 mentions for Mainz Biomed. Decoy Therapeutics' average media sentiment score of 1.44 beat Mainz Biomed's score of 0.75 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Positive
Mainz Biomed	Positive

Decoy Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 495.24%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Mainz Biomed	N/A	N/A	N/A

11.9% of Decoy Therapeutics shares are held by institutional investors. 1.7% of Decoy Therapeutics shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Decoy Therapeutics beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.68M	$974.40M	$7.71B	$12.20B
Dividend Yield	N/A	4.84%	38.15%	9.42%
P/E Ratio	N/A	1.53	23.60	23.63
Price / Sales	N/A	111.24	124.86	111.68
Price / Cash	N/A	20.06	164.25	58.78
Price / Book	0.46	8.47	12.77	6.01
Net Income	-$12.52M	-$2.70M	$120.21M	$331.99M
7 Day Performance	-10.16%	-2.29%	-0.98%	-0.63%
1 Month Performance	-8.70%	-4.64%	-2.53%	-3.04%
1 Year Performance	N/A	28.96%	9.66%	13.30%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	3.0156 of 5 stars	$5.04 +2.0%	$30.00 +495.2%	N/A	$2.68M	N/A	N/A	20	Positive News Short Interest Decrease Gap Up
LNAI Lunai Bioworks	0.9012 of 5 stars	$2.33 +0.4%	N/A	N/A	$10.52M	N/A	N/A	20	Positive News Gap Up
GDTC CytoMed Therapeutics	1.4849 of 5 stars	$0.99 +12.5%	N/A	-46.9%	$10.41M	$250K	N/A	N/A	Positive News Gap Up High Trading Volume
BCDA BioCardia	3.2585 of 5 stars	$0.85 -6.1%	$25.00 +2,840.8%	-63.8%	$10.29M	$60K	N/A	40	Short Interest Increase
CMMB Chemomab Therapeutics	3.155 of 5 stars	$1.36 -2.9%	$25.00 +1,738.2%	-68.8%	$10.08M	N/A	N/A	20	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. LNAI, GDTC, BCDA, CMMB, and MYNZ

How does Decoy Therapeutics compare to Lunai Bioworks?

Summary

How does Decoy Therapeutics compare to CytoMed Therapeutics?

Summary

How does Decoy Therapeutics compare to BioCardia?

Summary

How does Decoy Therapeutics compare to Chemomab Therapeutics?

Summary

How does Decoy Therapeutics compare to Mainz Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. LNAI, GDTC, BCDA, CMMB, and MYNZ

How does Decoy Therapeutics compare to Lunai Bioworks?

Is LNAI or DCOY more profitable?

Do analysts prefer LNAI or DCOY?

Do insiders and institutionals hold more shares of LNAI or DCOY?

Which has more risk & volatility, LNAI or DCOY?

Which has better earnings and valuation, LNAI or DCOY?

Does the media refer more to LNAI or DCOY?

Summary

How does Decoy Therapeutics compare to CytoMed Therapeutics?

Which has higher earnings and valuation, DCOY or GDTC?

Do analysts prefer DCOY or GDTC?

Which has more risk & volatility, DCOY or GDTC?

Is DCOY or GDTC more profitable?

Do institutionals & insiders believe in DCOY or GDTC?

Does the media refer more to DCOY or GDTC?

Summary

How does Decoy Therapeutics compare to BioCardia?

Which has more risk & volatility, DCOY or BCDA?

Does the media refer more to DCOY or BCDA?

Do analysts prefer DCOY or BCDA?

Which has preferable valuation & earnings, DCOY or BCDA?

Is DCOY or BCDA more profitable?

Do institutionals & insiders hold more shares of DCOY or BCDA?

Summary

How does Decoy Therapeutics compare to Chemomab Therapeutics?

Does the media prefer CMMB or DCOY?

Do analysts recommend CMMB or DCOY?

Which has more risk & volatility, CMMB or DCOY?

Do insiders and institutionals have more ownership in CMMB or DCOY?

Is CMMB or DCOY more profitable?

Which has better valuation and earnings, CMMB or DCOY?

Summary

How does Decoy Therapeutics compare to Mainz Biomed?

Which has better earnings and valuation, DCOY or MYNZ?

Does the media refer more to DCOY or MYNZ?

Which has more risk and volatility, DCOY or MYNZ?

Do analysts recommend DCOY or MYNZ?

Is DCOY or MYNZ more profitable?

Do insiders & institutionals hold more shares of DCOY or MYNZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools